The latest financial statement is for the quarter ending 2025-06-30.
| Cash Flow | 2025-06-30 |
|---|---|
| Net loss | -1,156 |
| Stock-based compensation | 27 |
| Bad debt recovery | -67 |
| Other noncash items | 14 |
| Prepaid expenses and other current assets | 359 |
| Inventory | 92 |
| Accounts payable and accrued liabilities | -939 |
| Accounts and other receivables | 328 |
| Gain on extinguishment of debt | 24 |
| Gain on changes in fair value of liability warrants | -3,663 |
| Depreciation expense | 8 |
| Deferred income tax | -6 |
| Net cash used in operating activities | -6,613 |
| Repayment of convertible notes payable | 811 |
| Proceeds from sale and issuance of securities, net | 10,859 |
| Net cash provided by financing activities | 10,048 |
| Effect of currency exchange rate changes on cash and cash equivalents | -5 |
| Net change in cash, cash equivalents and restricted cash | 3,430 |
ReShape Lifesciences Inc. (RSLS)
ReShape Lifesciences Inc. (RSLS)